Searchable abstracts of presentations at key conferences in endocrinology

ea0073oc12.3 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective effect in diabetic rats with experimental myocardial infarction

Simanenkova Anna , Minasian Sarkis , Karonova Tatiana , Vlasov Timur , Timkina Natalya , Khalzova Aleksandra , Shpilevaya Oksana , Shimshilashvili Anzhelika , Timofeeva Valeria , Borshchev Yury , Galagudza Mikhail

Background:Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having most prominent cardioprotective properties. Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated an ability to decrease heart failure manifestations, cardiovascular death frequency not having a certain influence on MI occurrence. On ...